• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

确定性放化疗联合抗程序性死亡受体1（PD-1）免疫疗法治疗不可切除食管鳞状细胞癌：一项多中心真实世界研究

Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study.

作者信息

Yang Xiongtao, Wang Xiaomin, Xiao Qin, Ge Xiaolin, Yu Nuo, Li Jiao, Feng Guojie, Zheng Ziyu, Jiang Yingying, Lu Lin, Xia Xiaojie, Deng Lei, Zhang Tao, Wang Wenqing, Liu Wenyang, Wang Jianyang, Xiao Zefen, Zhou Zongmei, Bi Nan, Wang Hui, Chen Cheng, Wang Xin

机构信息

Department of Oncology, Beijing Changping Hospital, Beijing, China.

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Cancer Biol Ther. 2025 Dec;26(1):2504726. doi: 10.1080/15384047.2025.2504726. Epub 2025 May 14.

DOI:10.1080/15384047.2025.2504726
PMID:40367097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12080274/
Abstract

Trial no. NCT04821778 registered in ClinicalTrials.gov.

摘要

试验编号NCT04821778已在ClinicalTrials.gov上注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f65/12080274/0a845de57ea4/KCBT_A_2504726_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f65/12080274/c6f5a080b238/KCBT_A_2504726_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f65/12080274/0fdb1b1d410a/KCBT_A_2504726_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f65/12080274/0a845de57ea4/KCBT_A_2504726_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f65/12080274/c6f5a080b238/KCBT_A_2504726_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f65/12080274/0fdb1b1d410a/KCBT_A_2504726_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f65/12080274/0a845de57ea4/KCBT_A_2504726_F0003_OC.jpg

相似文献

1
Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study.确定性放化疗联合抗程序性死亡受体1（PD-1）免疫疗法治疗不可切除食管鳞状细胞癌：一项多中心真实世界研究
Cancer Biol Ther. 2025 Dec;26(1):2504726. doi: 10.1080/15384047.2025.2504726. Epub 2025 May 14.
2
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.理由 311：替雷利珠单抗联合同期放化疗治疗局部食管鳞癌。
Future Oncol. 2021 Nov;17(31):4081-4089. doi: 10.2217/fon-2021-0632. Epub 2021 Jul 16.
3
Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial.程序性细胞死亡蛋白1抑制剂与确定性放疗联合免疫营养支持治疗食管鳞状细胞癌的疗效和安全性：一项II期多中心临床试验
Radiat Oncol. 2025 Apr 18;20(1):58. doi: 10.1186/s13014-025-02604-z.
4
Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial.替雷利珠单抗联合同步放化疗与同步放化疗治疗老年不可切除局部晚期食管鳞状细胞癌的多中心、随机、平行对照、II期临床试验
BMC Cancer. 2025 Feb 25;25(1):347. doi: 10.1186/s12885-025-13758-0.
5
Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial.替雷利珠单抗用于根治性同步放化疗后病理残留的食管鳞状细胞癌患者巩固治疗：一项多中心、随机、对照II期试验
Future Oncol. 2024 Dec;20(40):3397-3402. doi: 10.1080/14796694.2024.2432290. Epub 2024 Nov 26.
6
Case report: Long-term survival in synchronous double primary malignancies of lung adenocarcinomas and esophageal squamous cell carcinoma treated with definitive chemoradiotherapy and SBRT combined with anti-PD-1.病例报告：同步性双原发性肺腺癌和食管鳞状细胞癌经根治性放化疗、立体定向体部放疗联合抗程序性死亡蛋白1治疗后的长期生存情况
Front Immunol. 2025 Feb 14;16:1548176. doi: 10.3389/fimmu.2025.1548176. eCollection 2025.
7
Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.根治性放化疗可诱导不可切除局部晚期食管鳞癌的 T 细胞炎症肿瘤微环境。
J Gastroenterol. 2024 Sep;59(9):798-811. doi: 10.1007/s00535-024-02120-z. Epub 2024 May 31.
8
Exploring novel immunotherapy in advanced esophageal squamous cell carcinoma: Is targeting TIGIT an answer?探索晚期食管鳞状细胞癌的新型免疫疗法：靶向TIGIT是否是答案？
Esophagus. 2025 Apr;22(2):139-147. doi: 10.1007/s10388-024-01105-4. Epub 2025 Jan 23.
9
[Efficacy and safety of PD-1 inhibitors combined with chemotherapy for the treatment of local recurrence at the primary tumor site of ESCC following definitive chemoradiotherapy or radiotherapy].[PD-1抑制剂联合化疗治疗食管癌根治性放化疗或放疗后原发肿瘤部位局部复发的疗效与安全性]
Zhonghua Zhong Liu Za Zhi. 2025 May 23;47(5):418-425. doi: 10.3760/cma.j.cn112152-20240805-00327.
10
The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma.诱导化疗联合信迪利单抗序贯同步放化疗加信迪利单抗维持治疗不可切除的局部晚期食管鳞状细胞癌患者的疗效和安全性。
BMC Cancer. 2025 Jan 16;25(1):97. doi: 10.1186/s12885-025-13457-w.

本文引用的文献

1
Quality of life and survival outcomes of patients with inoperable esophageal squamous cell carcinoma after definitive radiation therapy: A multicenter retrospective observational study in China from 2015 to 2016.根治性放疗后不可切除食管鳞状细胞癌患者的生活质量和生存结局：一项2015年至2016年在中国进行的多中心回顾性观察研究。
J Natl Cancer Cent. 2023 May 10;3(2):150-158. doi: 10.1016/j.jncc.2023.05.001. eCollection 2023 Jun.
2
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial.信迪利单抗联合化疗诱导治疗后序贯同步放化疗用于局部晚期食管癌：一项概念验证性、单臂、多中心2期试验。
EClinicalMedicine. 2024 Feb 6;69:102471. doi: 10.1016/j.eclinm.2024.102471. eCollection 2024 Mar.
3
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.替雷利珠单抗联合化疗对比安慰剂联合化疗用于治疗晚期或转移性食管鳞癌（RATIONALE-306）：一项全球性、随机、安慰剂对照、III 期研究。
Lancet Oncol. 2023 May;24(5):483-495. doi: 10.1016/S1470-2045(23)00108-0. Epub 2023 Apr 17.
4
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.特瑞普利单抗联合根治性放化疗治疗局部晚期食管鳞癌（EC-CRT-001）：一项单臂、Ⅱ期临床试验。
Lancet Oncol. 2023 Apr;24(4):371-382. doi: 10.1016/S1470-2045(23)00060-8.
5
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.2020年食管鳞状细胞癌和食管腺癌发病率及死亡率的全球格局以及至2040年的预测：来自GLOBOCAN 2020的新估计
Gastroenterology. 2022 Sep;163(3):649-658.e2. doi: 10.1053/j.gastro.2022.05.054. Epub 2022 Jun 4.
6
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.信迪利单抗联合化疗一线治疗局部晚期或转移性食管鳞癌的随机、双盲、多中心 III 期临床研究（ORIENT-15）
BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714.
7
Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.度伐利尤单抗联合特瑞普利单抗与根治性放化疗治疗局部晚期食管鳞癌。
Cancer. 2022 Jun 1;128(11):2148-2158. doi: 10.1002/cncr.34176. Epub 2022 Mar 23.
8
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.替雷利珠单抗联合化疗用于初治的晚期食管鳞状细胞癌（JUPITER-06）：一项多中心3期试验
Cancer Cell. 2022 Mar 14;40(3):277-288.e3. doi: 10.1016/j.ccell.2022.02.007. Epub 2022 Mar 3.
9
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy.在非小细胞肺癌患者的放化疗过程中循环免疫细胞的动态变化支持更早地使用抗 PD-1/PD-L1 治疗。
Int J Radiat Oncol Biol Phys. 2022 Jun 1;113(2):415-425. doi: 10.1016/j.ijrobp.2022.02.003. Epub 2022 Feb 10.
10
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.纳武利尤单抗联合治疗晚期食管鳞癌。
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.